Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model

Abstract

Benzimidazole-based inhibitors of butyrylcholinesterase were designed and tested for their activity and selectivity in vitro , leading to compound (11d) that attenuated Aβ 25-35 -induced learning impairments in an Alzheimer's disease mouse model.